The GenBank accession numbers of nucleotide sequences reported in this article are HQ007312--HQ007350,JF759957--JF760203,JF906562--JF906700,JF759957--JF760203, KM011653--KM011849,KY713346-KY713582.

Introduction {#sec005}
============

HIV epidemic in Beijing, the capital of the largest developing country, has remained stable over the last 5 years. By Oct 31, 2016, the Beijing HIV epidemiology database cumulatively recorded 21,886 HIV-positive individuals since the identification of the first case of AIDS in 1985 in China. Most of these cases are among the so called, the floating population also known as people without the Beijing Hukou identification (74.2%) and men who have sex with men (MSM, \[66.0%\]). In 2003, Beijing launched a vigorous intervention campaign as part of the China National Free Antiretroviral Treatment Program (NFATP). The NFATP had markedly improved the prognosis of individuals with HIV in Beijing. By the end of 2016, 13,221 individuals have been treated with antiretroviral drugs through NFATP\[[@pone.0230779.ref001],[@pone.0230779.ref002]\]. However, there has been a general concern that the prevalence of transmitted drug resistance (TDR) could increase in parallel with the increasing availability of antiretroviral treatment (ART). Incidentally, such increase of TDR could negatively compromise the effectiveness of ART distribution program \[[@pone.0230779.ref003]\]. This concern is particularly important because in 2016, China implemented the World Health Organization (WHO) "treat-all", "treat-early" and "treatment as the prevention" policy \[[@pone.0230779.ref004],[@pone.0230779.ref005]\]. Previous epidemiological studies documented a relatively high genetic diversity and prevalence of TDR of HIV in Beijing\[[@pone.0230779.ref006]--[@pone.0230779.ref009]\]. However, data in those studies were collected from both the non-resident floating population and the Beijing residents (people with Beijing Hukou). Indeed, these studies lacked adequate stratification for origin of subjects, and very little molecular information was available for the residents and the floating population. Continued monitoring the trend of TDR in a specific population can provide important insights that may inform clinical practice indicating which first-line ART regimens should be used. The analysis of the *pol* region can serve double purpose:1) the detection of TDR and 2) for subtype determination and phylogenetic analysis. The latter, can give insight into patterns of HIV transmission, with direct implications for public health policy\[[@pone.0230779.ref010]\]. In this study, we aimed to characterize the trend of the HIV subtype diversity and the prevalence of TDR in Beijing residents from 2001 to 2016.

Materials and methods {#sec006}
=====================

Ethics {#sec007}
------

The Research Ethics Committee in Beijing Center for Disease Prevention and Control(CDC) approved the study. By law, consent was not required because these data were collected and analyzed in the course of routine public health surveillance.

Study patients {#sec008}
--------------

The Beijing HIV laboratory network (BHLN) was established in 1986 by the Beijing Municipal Commission of Health as a collaborative network of laboratories tasked to perform HIV diagnostic testing in Beijing. The BHLN includes a central HIV confirmatory laboratory in the Beijing CDC, four additional HIV confirmatory laboratories (DiTan, YouAn, Peking Union Medical College, and PLA General Hospital), and 280 HIV screening laboratories. The collaboration maintains a biobank with more than 50,000 stored samples collected from 21,886 individuals tested for HIV infection in Beijing since 1986. BHLN also maintains an HIV epidemiology database, which tracks patient diagnosed with HIV in Beijing and keeps records of the baseline of CD4 counts. BD FACS Calibur, BD FACS Canto II, and Beckman Coulter FC500 were used for CD4 cell counting. TDR was monitored in Beijing every year since 2006\[[@pone.0230779.ref006]\]. This involved a yearly survey of TDR among individuals newly diagnosed with HIV. A simple sampling scheme was designed to ensure broad representation of and feasibility of the survey. Briefly, samples were randomly selected from every other patient that was newly diagnosed with HIV infection. In addition, we included equal number of stored samples before the introduction of routine genotyping in Beijing, China in 2005. Inclusion criteria included, (1) being 18 years old or older, (2) being newly diagnosed with HIV and (3) not being pregnant. Individuals who reported previous use of antiretroviral drugs for treatment or prophylaxis were excluded from the present study.

HIV subtyping {#sec009}
-------------

HIV subtype was inferred by automated subtyping using Context-Based Modeling for Expeditious Typing (COMET)-HIV\[[@pone.0230779.ref011]\]. Sequences classified as "unassigned" by COMET were further analyzed using neighbor-joining phylogenetic analysis. The phylogenetic trees were constructed using the Kimura 2-parameter model, with 1,000 bootstrap replicates, using the Mega 6.0 software.

HIV TDR analyses {#sec010}
----------------

A population-based Sanger sequencing of the HIV protease gene and the deduced amino acid sequence from codon 1 through 300 of the reverse transcriptase gene of all specimens were analyzed using in-house methods\[[@pone.0230779.ref006],[@pone.0230779.ref012]\]. All virological testing were performed at two reference laboratories: the Division of Research on Virology and Immunology, China CDC (for the 2011 and 2013 survey) and the Beijing Central HIV confirmatory laboratory, Beijing CDC (for the survey of the other years). Both laboratories participated in external quality assessment schemes for genotypic TDR testing from the National AIDS Reference Laboratory of the National Center for AIDS/STD Prevention and Control. Three commercial sequencing companies(Beijing Sino Geno Max Co., Ltd, Beijing Tsingke Biological technology Co., Ltd, and Beijing TianyiHuiyuan Biological technology Co., Ltd) performed the sequencing using the ABI 3500 Analyzer. These companies provided the external quality assessment for sequencing performed by our research team.

The TDR was determined in two steps. Firstly, the prevalence of TDR was determined using the Stanford Calibrated Population Resistance (CPR) method, based on the 2009 WHO list of surveillance of TDR mutation(STDRM)\[[@pone.0230779.ref013]\]. Secondly, for patients harboring a virus with at least one TDR mutation, the Stanford drug-susceptibility algorithm (version 8.5) was used to classify sequences as susceptible (Stanford level 1 or 2), low-level resistance (Stanford level 3), intermediate-level resistance (Stanford level 4), or high-level resistance (Stanford level 5) to the drug classes (nucleoside reverse transcriptase inhibitors \[NRTIs\], non-NRTIs \[NNRTIs\], and protease inhibitors \[PIs\]) and specific drugs.

Data analysis {#sec011}
-------------

Baseline demographic data, transmission risk and CD4 cell counts were extracted from the Beijing HIV epidemiology database, ascertaining that patients information were anonymized and de-identified prior to analysis. Patients were grouped according to their residential status whether they hold the Beijing Hukou status (residents) or not (floating population). The Hukou system is a basic system of household registration in China. It officially identifies a person as a resident of an area. The Hukou includes identifying information such as name, parents, spouse, and date of birth. An individual without Hukou is regarded as an illegal resident.

The sampling time was divided into four phases: 2001--2008, 2009--2011, 2012--2014, and 2015--2016. Categorical and continuous data were compared using the χ^2^ test and with one-way ANOVA, respectively. The prevalence of TDR mutation was calculated and sequences containing at least one TDR mutation were further characterized as NRTIs, NNRTIs, and PIs. The risk factors for acquiring TDR mutations were estimated using logistic regression. The variables used for data analysis were sex, age (18--24, 25--44, 45--64, and ≥65 years), ethnicity, HIV subtype, CD4 cell counts (\<200, 200--349, 350--499, and ≥500 cells per μL), transmission risk group, and sampling phase. In the model, we included a binary response, indicating detection of any TDR mutation from each patient as an outcome.

We analyzed variables independently and included those that were associated (p\<0.1) with the outcome in the multivariable model. The results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs) and two-sided P values, with a P value of \<0.05 considered statistically significant. All analyses were performed using R (version 3.6.1)\[[@pone.0230779.ref014]\]. We used listwise deletion approach to handle missing data throughout the study. However, since 12.8% of data were missing for CD4 count, a sensitivity analysis was performed using multiple imputation to handle missing data (m = 5).

Results {#sec012}
=======

Study population {#sec013}
----------------

The Beijing HIV epidemiology database keeps records of new cases of HIV diagnosed among Beijing residents. From 2001 to 2016, 4,784 new cases of HIV recorded in the Beijing database, of which half (n = 2,350) were selected for the purpose of the current study. Thirty-five individuals were excluded from the final analysis (n = 2,315) for being younger than 18 years old. Of 2,315 participants, genotype information was available for 2,130 (92.0%). Specimens without genotype occurred at random and the prevalence was within the expected range ([S1 Table](#pone.0230779.s002){ref-type="supplementary-material"}). To ensure that exclusion of patients did not introduce a bias in the data analysis, patients information of the excluded population were compared with the remaining study group. Indeed, the demographic data, the CD4 counts, and transmission risk of individuals that were enrolled in the study were broadly similar to those who were excluded. Similarly, there was no significant difference for the age, sex and ethnicity between the four study periods. However, from 2009 to 2016, there was a significantly higher percentage of MSM compared to 2001--2008. The majority of participants were men (92.9%), and of Han ethnicity (96.2%). Median age was 34 years (interquartile range \[IQR\] 28--45), and men were younger than women (34 years \[IQR 28--45\] vs. 37 years \[IQR 29--49\]). Where available, the overall median baseline CD4 counts was 333 cells per μL (IQR 195--471). The predominant transmission risk groups were MSM (66.7%) or heterosexual contact (26.6%) ([Table 1](#pone.0230779.t001){ref-type="table"}).

10.1371/journal.pone.0230779.t001

###### Baseline characteristic by sampling phase.

![](pone.0230779.t001){#pone.0230779.t001g}

                                                                    2001--2008      2009--2011      2012--2014      2015--2016      Total
  ----------------------------------------------------------------- --------------- --------------- --------------- --------------- ---------------
  Sex                                                                                                                               
  Men                                                               306(85.7)       461(92.8)       686(93.8)       526(96.5)       1979(92.9)
  Women                                                             51(14.3)        36(7.2)         45(6.2)         19(3.5)         151(7.1)
  Age at diagnosis(years)[^a^](#t001fn004){ref-type="table-fn"}     34(28--42)      35(28--45)      34(28--46)      34(28--47)      34(28--45)
  CD4 counts (cells per μL)[^b^](#t001fn005){ref-type="table-fn"}   323(200--433)   329(191--441)   358(228--519)   304(162--450)   333(195--471)
  Transmission risk group[^c^](#t001fn006){ref-type="table-fn"}                                                                     
  Heterosexual                                                      119(36)         155(32.0)       178(24.5)       115(21.3)       567(27.2)
  MSM                                                               168(50.8)       304(62.7)       534(73.5)       414(76.5)       1420(68.1)
  IDU                                                               23(6.9)         21(4.3)         13(1.8)         12(2.2)         69(3.3)
  Blood transfusion                                                 21(6.3)         4(0.8)          2(0.3)          0(0)            27(1.3)
  Mother to child                                                   0(0)            1(0.2)          0(0)            0(0)            1(0.05)
  Subtype                                                                                                                           
  A1                                                                3(0.8)          4(0.8)          5(0.7)          2(0.4)          14(0.7)
  B                                                                 151(42.3)       119(23.9)       111(15.2)       69(12.7)        450(21.1)
  C                                                                 9(2.5)          5(1)            7(1)            1(0.2)          22(1)
  F1                                                                1(0.3)          0(0)            0(0)            0(0)            1(0)
  G                                                                 3(0.8)          1(0.2)          0(0)            0(0)            4(0.2)
  01_AE                                                             119(33.3)       230(46.3)       378(51.7)       277(50.8)       1004(47.1)
  02_AG                                                             0(0)            0(0)            3(0.4)          1(0.2)          4(0.2)
  06_cpx                                                            3(0.8)          0(0)            0(0)            0(0)            3(0.1)
  07_BC                                                             56(15.7)        123(24.7)       172(23.5)       140(25.7)       491(23.1)
  08_BC                                                             7(2.0)          4(0.8)          2(0.3)          3(0.6)          16(0.8)
  55_01B                                                            0(0)            3(0.6)          7(1)            3(0.6)          13(0.6)
  57_BC                                                             1(0.3)          0(0)            0(0)            0(0)            1(0)
  59_01B                                                            0(0)            0(0)            2(0.3)          2(0.4)          4(0.2)
  63_02A1                                                           0(0)            1(0.2)          0(0)            0(0)            1(0)
  65_cpx                                                            1(0.3)          1(0.2)          4(0.5)          6(1.1)          12(0.6)
  67_01B                                                            0(0)            1(0.2)          1(0.1)          0(0)            2(0.1)
  68_01B                                                            0(0)            0(0)            2(0.3)          2(0.4)          4(0.2)
  URFs                                                              3(0.8)          5(1)            37(5.1)         39(7.2)         84(3.9)
  Ethnicity                                                                                                                         
  Han                                                               334(93.6)       472(95.0)       705(96.4)       538(98.7)       2049(96.2)
  Minority                                                          23(6.4)         25(5.0)         26(3.6)         7(1.3)          81(3.8)

Data are n (%) or median (IQR).

MSM = Men who have sex with men.

IDU = Injecting drug user

^a^Data for n = 2,125.

^b^Data for n = 1,858.

^c^Data for n = 2,084.

URFs = Unique Recombinant Forms

Temporal trends of HIV subtypes {#sec014}
-------------------------------

The most common HIV subtype and circulating recombinant forms(CRFs) circulating among Beijing residents were CRF01_AE (47.1%), CRF07_BC(23.1%), B(21.1%), and URF(3.9%). Additional clades including subtypes A1, C, F1, CRF02_AG, CRF06_cpx, CRF08_BC, CRF55_01B, CRF57_BC, CRF59_01B, CRF63_02A1, CRF65_cpx, CRF67_01B, and CRF68_01B were present in less than 1.0% of persons ([Fig 1](#pone.0230779.g001){ref-type="fig"}). [Table 1](#pone.0230779.t001){ref-type="table"} presents the temporal trends for these main subtypes and CRFs. There was a substantial increase in the prevalence of HIV CRF07_BC over time. The prevalence of CRF01_AE increased and stabilized. Interestingly, the prevalence of subtype B continuously declined throughout the period of the study.

![Phylogenetic analysis of *pol* sequences.\
Phylogenetic tree was constructed using neighbor-joining methods (Mega 6.0). The black solid squares indicate reference sequences from the Los Alamos HIV sequence database.](pone.0230779.g001){#pone.0230779.g001}

Distribution of subtypes and CRFs {#sec015}
---------------------------------

The percentage of subtypes and CRFs circulating in Beijing varied significantly by sex, age, ethnicity, and transmission risk group. [Table 2](#pone.0230779.t002){ref-type="table"} shows the subtype diversity within demographic subgroups. MSM were found to predominantly have CRF01_AE virus. Individuals with heterosexual transmission risk had a much greater variety of HIV, with the most frequent subtype being CRF01_AE. CRF07_BC infections were more common in injecting drug users(IDU). The phylogenetic analysis showed no evidence of laboratory carry-over contamination.

10.1371/journal.pone.0230779.t002

###### Subtype assignment by selected characteristics.

![](pone.0230779.t002){#pone.0230779.t002g}

                                                                        CRF01_AE    B           CRF07_BC    URFs       Other
  --------------------------------------------------------------------- ----------- ----------- ----------- ---------- ----------
  sex                                                                                                                  
  Men                                                                   959(95.5)   419(93.1)   443(90.2)   78(92.9)   80(79.2)
  Women                                                                 45(4.5)     31(6.9)     48(9.8)     6(7.1)     21(20.8)
  Age at diagnosis(years) group[^a^](#t002fn002){ref-type="table-fn"}                                                  
  \<25                                                                  154(15.4)   44(9.8)     67(13.7)    10(11.9)   9(8.9)
  25--44                                                                617(61.5)   298(66.5)   259(53)     48(57.1)   56(55.4)
  45--64                                                                198(19.7)   92(20.5)    132(27)     20(23.8)   31(30.7)
  65-                                                                   34(3.4)     14(3.1)     31(6.3)     6(7.1)     5(5)
  CD4 counts (cells per μL)[^b^](#t002fn003){ref-type="table-fn"}                                                      
  \<200                                                                 252(27.6)   106(29)     75(17.6)    18(23.4)   22(28.9)
  200--349                                                              261(28.6)   101(27.6)   121(28.3)   22(28.6)   14(18.4)
  350--499                                                              207(22.7)   86(23.5)    128(30)     20(26)     14(18.4)
  \>499                                                                 192(21.1)   73(19.9)    103(24.1)   17(22.1)   26(34.2)
  Transmission risk group[^c^](#t002fn004){ref-type="table-fn"}                                                        
  Heterosexual                                                          229(23.2)   134(30.7)   130(27.0)   18(22.0)   56(59.6)
  MSM                                                                   744(75.2)   286(65.4)   300(62.2)   59(72.0)   31(33.0)
  IDU                                                                   13(1.3)     7(1.6)      39(8.1)     5(6.1)     5(5.3)
  Blood transfusion                                                     3(0.3)      10(2.3)     12(2.5)     0(0)       2(2.1)
  Mother to child                                                       0(0)        0(0)        1(0.2)      0(0)       0(0)
  Ethnicity                                                                                                            
  Han                                                                   977(97.3)   428(95.1)   471(95.9)   82(97.6)   91(90.1)
  Minority                                                              27(2.7)     22(4.9)     20(4.1)     2(2.4)     10(9.9)

Data are n (%).

^a^Data for n = 2,125.

^b^Data for n = 1,858.

^c^Data for n = 2,084.

URFs = Unique Recombinant Forms.

MSM = Men who have sex with men.

IDU = Injecting drug users.

Other = A1, C, F1, CRF02_AG, CRF06_cpx, CRF08_BC, CRF55_01B, CRF57_BC, CRF59_01B, CRF63_02A1, CRF65_cpx, CRF67_01B, and CRF68_01B.

Prevalence and patterns of TDR {#sec016}
------------------------------

The overall prevalence of TDR was 4.5% (95% CI: 3.6--5.4), with mutations associated with PIs being the most common form of mutation (2.8%, 95% CI:2.1--3.5), followed by mutations associated with NRTIs (1.0%, 95% CI:0.6--1.5) and NNRTIs (0.9%, 95% CI: 0.6--1.4). Dual-class resistance was uncommon (0.28%, 95% CI:0.1--0.6). Women tended to have lower prevalence of TDR than men. In the heterosexual transmission risk group, men had twice the prevalence of TDR than women (4.1%, 95% CI: 2.4--6.1 in men, vs. 1.6%, 95% CI: 0.2--4.6 in women). Notably, the prevalence of TDR in CRF07_BC viruses was significantly lower than in other viral strains. The prevalence of TDR did not differ significantly between transmission risk groups.

The most prevalent mutation associated with PIs TDR, M46L (1.9%, 95% CI: 1.4--2.6), was present in 4.0% (95% CI:2.9--5.3) of the CRF01_AE HIV strains tested. The most frequent mutation associated with NRTIs TDR were the thymidine analogue mutations (TAM), of which the most prevalent were the mutation of M41L (0.2%, 95% CI:0.05--0.4), followed by mutation of M184V(0.28%, 95% CI:0.1--0.6). The K103N, Y181C, and K101E were the most common mutations associated with NNRTIs TDR, which were found in 0.28% (95% CI:0.1--0.6), 0.23% (95% CI:0.07--0.5), and 0.23% (95% CI:0.07--0.5) of individuals, respectively. No polymorphisms and mixture base were found in the TDR position. Of the 95 sequences with at least one TDR mutation, resistance was confined to a single drug class for 89 sequences (93.7%, 95% CI: 87.9--97.7), and 87 sequences (91.6%, 95% CI:85.2--96.3) had a single mutation. Of the 95 sequences, 21(22.1%, 95% CI: 14.4--31.0) had high-level resistance (Stanford 5), 17 (17.9%, 95% CI:11.0--26.2) had intermediate-level resistance (Stanford 4), and 49 (51.6%, 95% CI:41.6--61.6) had low-level resistance (Stanford 3). Seventeen sequences (17.9%, 95% CI: 10.1--26.2) showed loss of susceptibility to NRTIs (AZT 8.4%, 3TC 8.4%, TDF 3.2%), 21 sequences (22.1%, 95% CI:14.4--31.0) to NNRTIs (EFV 22.1%, ETR 13.7%, NVP 22.1%, RPV 14.7%), and 55 sequences (57.9%, 95% CI:47.9--67.6) to PIs (LPV 2.1%, NFV 58.9%).

Time trends and correlates of TDR {#sec017}
---------------------------------

The annual prevalence of TDR in our study ranged from 1.7% to 10.3% of the samples tested. There was no statistically significant decline in the annual trendof TDR over the study period when using the univariable (p = 0.08) or multivariable analysis (p = 0.14) ([S1 Fig](#pone.0230779.s001){ref-type="supplementary-material"}). There was a significant decline in the prevalence of TDR over between 2001 and 2016 when both the univariable and multivariable analyses were performed ([Fig 2](#pone.0230779.g002){ref-type="fig"}, [Table 3](#pone.0230779.t003){ref-type="table"}). Comparing the TDR by the ARTclasses, the PIs followed the same time trend as the overall prevalence (p = 0.0003), but there was no significant change in time trend for NRTIs or NNRTIs (p = 0.34 for NRTIs, p = 0.37 for NNRTIs) ([Fig 2](#pone.0230779.g002){ref-type="fig"}).

![Temporal trends of prevalence of transmitted drug resistance by sampling phase.\
Vertical bars = 95% CI; The trend line is predicted prevalence of transmitted drug resistance; NRTIs = nucleoside reverse transcriptase inhibitors; NNRTIs = non-NRTIs; PIs = protease inhibitors.](pone.0230779.g002){#pone.0230779.g002}

10.1371/journal.pone.0230779.t003

###### Demographic and clinical factors associated with TDR.

![](pone.0230779.t003){#pone.0230779.t003g}

                                                                        Number of sequences   Prevalence of TDR[^\#^](#t003fn006){ref-type="table-fn"}   Univariable analysis[\*](#t003fn004){ref-type="table-fn"}            Multivariable analysis[†](#t003fn005){ref-type="table-fn"}   
  --------------------------------------------------------------------- --------------------- ---------------------------------------------------------- ----------------------------------------------------------- -------- ------------------------------------------------------------ --------
  Sex                                                                                                                                                                                                                                                                                      
  Men                                                                   1979                  93(4.7)                                                    Reference                                                                                                                         
  Women                                                                 151                   2(1.3)                                                     0.27(0.04--0.87)                                            0.07     0.26(0.04--0.85)                                             0.06
  Age at diagnosis(years) group[^a^](#t003fn007){ref-type="table-fn"}                                                                                                                                                                                                                      
  \<25                                                                  284                   13(4.6)                                                    Reference                                                                                                                         
  25--44                                                                1278                  59(4.6)                                                    1.01(0.56--1.95)                                            0.98                                                                  
  45--64                                                                473                   17(3.6)                                                    0.78(0.37--1.66)                                            0.5                                                                   
  65-                                                                   90                    4(4.4)                                                     0.97(0.27--2.82)                                            0.96                                                                  
  CD4 counts (cells per μL)[^b^](#t003fn008){ref-type="table-fn"}                                                                                                                                                                                                                          
  \<200                                                                 473                   20(4.2)                                                    Reference                                                                                                                         
  200--349                                                              519                   23(4.4)                                                    1.05(0.57--1.95)                                            0.88                                                                  
  350--499                                                              455                   18(4.0)                                                    0.93(0.48--1.79)                                            0.83                                                                  
  \>499                                                                 411                   22(5.4)                                                    1.28(0.69--2.40)                                            0.43                                                                  
  Transmission risk group[^c^](#t003fn009){ref-type="table-fn"}                                                                                                                                                                                                                            
  Heterosexual                                                          567                   20(3.5)                                                    Reference                                                                                                                         
  MSM                                                                   1420                  67(4.7)                                                    1.35(0.83--2.31)                                            0.24                                                                  
  IDU                                                                   69                    4(5.8)                                                     1.68(0.48--4.61)                                            0.36                                                                  
  Blood transfusion                                                     27                    1(3.7)                                                     1.05(0.06--5.36)                                            0.96                                                                  
  Ethnicity                                                                                                                                                                                                                                                                                
  Han                                                                   2049                  94(4.6)                                                    Reference                                                                                                                         
  Minority                                                              81                    1(1.2)                                                     0.26(0.01--1.19)                                            0.18                                                                  
  Sampling Phase                                                                                                                                                                                                                                                                           
  2001--2008                                                            357                   24(6.7)                                                    Reference                                                                                                                         
  2009--2011                                                            497                   23(4.6)                                                    0.58(0.33--1.01)                                            0.05     0.63(0.34--1.16)                                             0.13
  2012--2014                                                            731                   25(3.4)                                                    0.59(0.35--1.02)                                            0.05     0.43(0.23--0.79)                                             0.006
  2015--2016                                                            545                   23(4.2)                                                    0.51(0.19--1.2)                                             0.15     0.54(0.29--0.999)                                            0.048
  Subtype                                                                                                                                                                                                                                                                                  
  01_AE                                                                 1004                  61(6.1)                                                    Reference                                                                                                                         
  07_BC                                                                 491                   5(1)                                                       0.16(0.06--0.36)                                            \<0.01   0.16(0.06--0.37)                                             0.0001
  B                                                                     450                   19(4.2)                                                    0.68(0.39--1.13)                                            0.15     0.58(0.33--0.98)                                             0.05
  URFs                                                                  84                    4(4.8)                                                     0.77(0.23--1.94)                                            0.63     0.88(0.26--2.24)                                             0.81
  Others                                                                101                   6(5.9)                                                     0.98(0.37--2.15)                                            0.96     0.99(0.37--2.22)                                             0.99

MSM = Men who have sex with men.

IDU = Injecting drug user

OR = odds ratio.

\*Univariable logistic regression analysis.

^†^Multivariable logistic regression analysis.

^\#^Data are n (%).

^a^Data for n = 2,125.

^b^Data for n = 1,858.

^c^Data for n = 2,084.

TDR = transmitted drug resistance.

Other = A1, C, F1, CRF02_AG, CRF06_cpx, CRF08_BC, CRF55_01B, CRF57_BC, CRF59_01B, CRF63_02A1, CRF65_cpx, CRF67_01B, and CRF68_01B.

URFs = Unique Recombinant Forms.

Multivariable analysis revealed association between TDR, and HIV subtype and sampling phase, with risk reduced for CRF07_BC and phase 2012--2016, compared to CRF01_AE and phase 2001--2008 ([Table 3](#pone.0230779.t003){ref-type="table"}). In two sensitivity analyses, which included individuals younger than 18 years old, and excluded individual transmission risk group respectively, the magnitude of the associations did not change significantly(data not shown).

CD4 counts data missing {#sec018}
-----------------------

Because the rate of missing CD4 counts data was relatively high (12.8%), multiple imputation was used in the logistics analysis([S2 Table](#pone.0230779.s003){ref-type="supplementary-material"}). In addition, four sensitivity experiments were carried out by excluding individual sampling phase ([S3](#pone.0230779.s004){ref-type="supplementary-material"}--[S6](#pone.0230779.s007){ref-type="supplementary-material"} Tables). Indeed, neither the multiple imputation method nor the sensitivity experiments proved that CD4 counts was associated with TDR.

Discussion {#sec019}
==========

This study prospectively analyzed nucleotide and amino acid sequences to decipher the temporal trends in prevalence of TDR and the genetic diversity of HIV among 2,130 Beijing residents. A high degree of viral diversity was observed with multiple subtypes and CRFs among Beijing residents. CRF01_AE, CRF07_BC, and subtype B were the most common clades circulating among Beijing residents. The trends for CRF01_AE and CRF07_BC increased over time, whereas B had a decreasing trend. A similar trend was observed in other provinces across China \[[@pone.0230779.ref015]--[@pone.0230779.ref017]\]. Indeed, Beijing is a popular destination for floating populations that come from other provinces and other countries. It is likely that the high HIV genetic diversity observed in this study population could be due to the influx of non-residents and viral lineages that circulate in other provinces or other countries \[[@pone.0230779.ref018]\].

The overall prevalence of TDR among residents newly diagnosed with HIV infection in Beijing was low. There was a apparent declining trend during study period, which was consistent with the results of other molecular diversity studies in other provinces of China \[[@pone.0230779.ref015]--[@pone.0230779.ref017],[@pone.0230779.ref019],[@pone.0230779.ref020]\]. There was no significant difference in the prevalence of TDR when comparing the sex, the age, the transmission risk groups and the ethnicity of the study population. Of the three main clades (CRF01_AE, CRF07_BC, and subtype B), CRF07_BC had the lowest prevalence of TDR. This prevalence was significantly lower than reported in Mexico, San Diego (USA), and Europe\[[@pone.0230779.ref021]--[@pone.0230779.ref023]\]. The low prevalence of TDR is most likely due to a short period exposure to antiretroviral drugs. It is only in 2003 that the implementation of NFATP was widely applied in Beijing. Indeed, Beijing has a relatively shorter experience using ART compared to North American and Europe, which started using ART in middle of 1990. Results from this study also indicated there was high prevalence of TDR for PIs and a low prevalence of TDR for NRTIs and NNRTIs. This was unexpected, given that NRTIs and NNRTIs are widely used in Beijing as first-line treatment and the Lopinavir/Ritonavir is the only ART drug prescribed as a second-line regimen. The higher prevalence of PIs can be attributed to an unexpectedly high proportion of participants with CRF01_AE virus that harbored M46L mutation, which could cause low-level drug resistance to nelfinavir (NFV). Because NFV is not prescribed in China, this high prevalence has little practical meaning.

Beijing is an international cosmopolitan city and is a human mobility hub which maintains a very intense movement of people, from both within China and overseas. People move to Beijing because they are attracted to employment, medical need, and tourism. Three quarter of the 21,886 individuals with HIV infection in Beijing are floating population \[[@pone.0230779.ref001]\]. Often, it is commonly accepted that the floating population dominated the Beijing HIV epidemic. However, could IDUs infected with HIV in Sinkiang or former blood donors in Henan province, for instance, truly represented the epidemic of Beijing? Being diagnosed in Beijing does not necessarily mean that the infection occurred in Beijing. If patients were infected in their home province, though diagnosed in Beijing, they actually reflected the epidemic of their hometown. Moreover, floating population and residents are different groups of people, with the former coming from across China and the latter only from Beijing. Floating populations come and go in Beijing, but residents will always be there. Therefore we suggested that floating population most likely represent imported HIV epidemic, while residents represent ongoing transmission of HIV and could better represent the epidemic in Beijing.

The data presented in this study sheds light and provides new insights to better understand the molecular epidemiology of HIV and will assist in the development of the prevention and the treatment strategies for the control of the HIV/AIDS epidemic in Beijing and beyond. Because most patients generally respond well to first-line regimens, the routine genotype testing is not required prior to treatment. There are no pressing needs for expensive second-line regimens. Although NFV is not used as part of the first-line ART regimens in Beijing, it is worth noting that there are at least a small number (1.9%) of people harbor viruses with TDR to these drugs. Thus, the use of NFV in Beijing should be examined with caution. Vaccine designer in Beijing should take the fact that CRF01_AE, CRF07_BC and subtype B constituted more than 90% of all the clades into consideration in select appropriate candidate HIV strains. Viral load (VL) kit manufacturer should also know this in designing the primer to ensure accurate HIV RNA quantitation of non-B subtypes in Beijing. Interestingly, as shown in [Table 3](#pone.0230779.t003){ref-type="table"}, the odds ratio and p value for women was inconsistent. We speculated that the sample size of women is too small to discern the significant difference in this study. Our recent national survey with larger sample size of women confirms that our speculation is correct \[[@pone.0230779.ref024]\].

To our knowledge this is the largest study to cover the longest-period (16 years) on HIV subtypes and TDR in Beijing. We analyzed sequences representing half of all known residents cases of HIV infection that were diagnosed in Beijing during 2001--2016, which allowed us to carry out this analysis with reasonable accuracy.

However, several limitations are worth mentioning. Firstly, the study population was limited for women. Secondly, VL information was not available, which did not permit the evaluation of the association between VL and TDR.

In summary, this study of 2,130 HIV infected patients show that there is a high genetic heterogeneity of HIV in Beijing than previously appreciated. However, the prevalence of TDR was low with a declining trend over nearly a two decades period. The prevalence of TDR was lower in individuals infected with CRF07_BC than those infected with CRF01_AE. The widespread distribution of ART did not necessarily lead to an increase of TDR. To better formulate a more efficacious response policy on HIV/AIDS in a heterogenic city such as Beijing, residents and floating population should be analyzed separately.
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Dear Editor and Reviewers:

We would like to thank Plos One for giving use the opportunity to revise our manuscript. We thank reviewers for their careful read and thoughtful comments on previous draft. We have carefully taken their comments into consideration in preparing our revision. Below is our response to their comments.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Yes, we are sure that our manuscript meets Plos One' style requirements.

2\. Our internal editors have looked over your manuscript and determined that it is within the scope of our Antimicrobial Resistance call for papers. This collection of papers is headed by a team of Guest Editors for PLOS ONE: Kathryn Holt (Monash University and London School of Hygiene and Tropical Medicine), Alison H. Holmes (Imperial College London), Alessandro Cassini (WHO Infection Prevention and Control Global Unit), Jaap A. Wagenaar (Utrecht University). The Collection will encompass a diverse range of research articles; additional information can be found on our announcement page: <https://collections.plos.org/s/antimicrobial-resistance>. If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

Yes, we are greatly pleased that our manuscripts could be considered for this collection.

3\. Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>

Yes, we included the full name of the research ethics committee that approved our study. We added the same text to the "Ethnics Statement" field of the submission form.

Additional Editor Comments (if provided):

This a longitudinal study of HIV subtypes and drug resistance in China.

The methods and analyses are sound. However, the manuscript requires careful revision by a native English speaker or a professional editing service.

Yes, we invited Dr. John Mokili, from Viral Information Institute at San Diego State University for critical review and insightful editing of the manuscript.

The population size is quite large although heavily skewed towards men. Does this reflect the gender distribution of HIV in China?

Yes, this is exactly real gender distribution of HIV in Beijing, the capital of China. Of the 17,421 individuals living with HIV in Beijing by the end of 2017, 95.1% were men. The gender ratio of individuals with HIV varied greatly between provinces in China. The national gender ratio of men vs. women of people with HIV is 3.7:1 in 2016.

Lines 69 and 80: what is "floating population"?

To get a full appreciation of what "floating population" means we must turn first to Hukou system, the basic system of household registration in China. The Hukou system officially identifies a person as a resident of an area and includes identifying information such as name, parents, spouse, and date of birth. The Hukou system is of critical importance to people in China. Someone without Hukou is regarded as an illegal resident. The Hukou is analogous to the US Permanent Resident Card, but it has a more important meaning to Chinese people. Hukou is the system of household registration used in China. The system itself is more properly called \"Huji\", and has origins in ancient China. Due to its connection to social programs, which assigns benefits based on agricultural and non-agricultural residency status (often referred to as rural and urban), the Hukou system is sometimes likened to a form of caste system.

Floating population is a terminology used to describe a group of people who reside in a given population for a certain amount of time and for various reasons, but are not generally considered part of the official census count \[1\].

In our study, we categorized the residents and floating population based on Hukou system. We defined patients with Beijing Hukou as residents, and those without Beijing Hukou as floating population. To make two extreme instances, if Chinese people with Beijing Hukou lived in U.S for 20 years or more, we still regard them as Beijing residents, unless they checked out the Beijing Hukou. In the contrary class, if people without Beijing Hukou (certainly have the local Hukou, every Chinese people have Hukou) lived in Beijing for 20 years or more, we still call them floating population. Of course, people in these two instances were minority. Because Hukou is always associated with ware fare, education, medical services, old age housekeeping, most Chinese people live their most of their life in the place where their Hukou belong. Moreover, in China, no one could always float, they will reside in the end.

1.<http://wikipedia.moesalih.com/Floating_population>.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Yes, our manuscript concerned two of the most important topics of HIV in Beijing: the subtype and the TDR, both of which have important implications. We believe our finding has the potential to transform current understanding of the relationship between antiretroviral therapy (ART) rollout and prevalence of transmitted drug resistance(TDR). There has long been a concern that TDR has increased in parallel with the increasing availability of antiretroviral treatment (ART), which can compromise the effectiveness of first-line ART regimens. The most significant finding of our study is that we observed a declining trend of TDR. This is amazing. Why? Because the reasons for the declining trends in prevalence of TDR in Beijing would also apply to other regions. Our findings provide hope to individuals with HIV on ART in regions with high TDR burden, and serve as an indicator of the likely future trend.

Reviewer \#1: Partly

Reviewer \#2: Partly

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

Yes, the statistical analysis was performed using R based on the book by Robert I Kabacoff, "R in Action: Data Analysis and Graphics with R". Patient age was discretized (18-24, 25-44,154 45-64, and ≥65 years) and CD4 cell count was discretized (\<200, 200-349, 155 350-499,and ≥500 cells per μL). Variables were analyzed independently and only those that were associated (p\<0.1) with the outcome in the multivariable model were included in the final analysis. Multivariable logistic regression was used to explore the relation TDR and sex, age, ethnicity, HIV subtype, CD4 cell count, transmission risk group, and sampling phase. The analysis to estimate the trend of TDR over time was examined. Using a more rigorous method- the Multiple Imputation(MI)- missing data were analyzed to reduce bias. What was possible has been done. In short, we believe that we have winkled out all the useful meanings beneath these materials.

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Yes, we deposited all our sequences in the HIV databases. We are very happy to share our study with our colleagues not only in China, but also from the world. We are willing to share our finding in detail in all kind of formulation.

Reviewer \#1: Yes

Reviewer \#2: No

4\. Is the manuscript presented in an intelligible fashion and written in a standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Yes, we invited Dr. John Mokili, from Viral Information Institute at San Diego State University for critical review and insightful editing of the manuscript.

Reviewer \#1: No

Reviewer \#2: No

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The investigators have analysed large size of drug resistance data and adds value to the medical literature substantially. Few things to be considered before publishing this manuscript:

1\) The manuscript English could be improved as much as possible.

Yes, as any non-native English speakers, we invariably encounter great difficult in writing manuscript in standard English. However, this will not pose any problem. Because we invited Dr. John Mokili, from Viral Information Institute at San Diego State University for critical review and insightful editing of the manuscript.

2\) At least a brief mention of laboratory methodology and instrumentation is needed. Eg. Instruments used for CD4 count, Gene sequencing, etc.,

Yes, we described the instruments in Methods section.

3\) The study conducted with the samples collected between 2001 - 2016, but the break up used could be pattern based rather than convenient sake. Eg. 2001-2004, 2005-2008, 2009-2012, 2012-2015 or so.

Yes, we established four sampling phases for the convenient sake: 2001-2008, 2009-2011, 2012-2014, and 2015-2016.

4\) The drug resistance patterns also could be analysed with the year break up with the pattern to observe the trends better.

Yes, we analyzed the TDR patterns with the year break-up, however, the declining trend lost the significance. Small sample size may be the reason. So we balanced the visuality and statistic significance and established four sampling phases. We also provided the annual prevalence of TDR in supplementary results. Even in annual analysis, the sample before 2005 was too small, so we group them together.

5\) Polymorphisms and mixtures in the drug resistance positions have not been addressed. If not observed, that could be mentioned.

Yes, we did not identify polymorphisms and mixture base in the TDR position. We mentioned that in our manuscript.

6\) Looks like the study did not include plasma viral load (PVL) data and if so, that could be listed in the study limitation as this could potentially affect the study data. If PVL is available, IQR for the available data could be mentioned.

Yes, we did not include the plasma viral load (PVL) data. We listed this in the study limitation. Indeed, we also maintained a treatment database, which include baseline VL and follow up VL record. In the future study, we will link the baseline VL using the unique ID card number. Now the condition is still not ripe.

7\) Figure 2 is not readable.

Yes, we rewrote the Figure 2.

Reviewer \#2: The manuscript by Lu and colleagues describes high HIV genetic diversity and declining trends in the prevalence of overall and some class-specific HIV drug resistance in Beijing between 2001-2016. While the high genetic diversity of HIV is well known globally, the observed declines in HIV drug resistance in Beijing are of relevance and contrast trends observed in other settings. The discussion of the data to potentially explain these findings is well-balanced. However, some aspects of the methods and presentation of results would benefit from further clarification. Despite being a national data source, increased transparency on potential selection bias is strongly recommended. The manuscript would also benefit from additional grammatical review. Below are specific comments:

Title:

The title of the manuscript should included further specification of the study population (i.e., newly diagnosed residents).

Yes, we rewrote the title.

Abstract:

Line 38 -- The outcome for the statement, "The overall prevalence was 4.5%", should be specified.

Yes, we specified the overall prevalence of TDR by ART class, ie. NRTIs, NNRTIs, and PIs.

Introduction:

Line 69 -- It is unclear at first mention what a floating population is.

Yes, we explained the floating population briefly at first mention and explained it in detail in method.

Methods:

Line 96 -- The manuscript states that all data were collected and analyzed in the course of routine public health surveillance, but does this include retrospective analysis of stored specimen? Were patients notified if they had drug resistant strains?

Yes, our study included retrospective analysis of the stored specimen. The study period was divided into three phase based on the history of TDR test in Beijing. Before 2006, when an in-house TDR test was first introduced to Beijing the analysis of the samples collected before that was performed retrospective. The patients were not notified of the TDR result. Between 2007-2012, TDR test was mainly for public health purposes. The results of the TDR test were occasionally sent to the doctors in charge of diagnosis of the patients. We are not very sure whether the patients knew their result. Until then, the guideline for testing for TDR in conjunction with ART treatment needed to be reviewed. During 2001-2007, HIV patients with CD4 counts at 200 cells per μL or less were eligible for free ART. In 2008, the CD4 count threshold for treatment was increased to 350 cells per μL. In this context, the results of the TDR were given to all including the newly diagnosed patients if they met the criterion for treatment. Thirdly, from 2013 to date, we provide free routine TDR test for about half of newly diagnosed patients. All patients are informed of their test results. In the future, we plan to increase the coverage to provide free TDR test to all the patients.

Line 104 -- It needs to be specified that it is 21,886 individuals ever diagnosed with HIV infection

Yes, we specified the 21,886 individuals ever diagnosed, not the patients living with HIV.

Line 110-11: It is unclear what "standardized sampling strategy" means and why only half of the samples from all newly identified individuals were included in the study. Further clarification is needed.

Yes, our standardized sampling strategy is a simply sampling strategy. Our concept is "the simpler, the better". In the new revision, we described it as the simple sampling strategy. For consistency, we simply collected about half of the newly identified patients. We believed the 50% sampling rate is high enough to represent the HIV epidemiology in Beijing. We have to consider the cost-effectiveness of the surveillance program. Each TDR test cost us about 50 U.S dollars. So this article worth 100,000 US dollars, the sum of the money of a Mercedes-Benz. This was so dear for us. In the future, we plan to extend the TDR test to all the newly diagnosed patients.

Line 153 -- The term "multivariable" would be more appropriate than "multivariate", consistent with what is used later in the manuscript (e.g., Line 159).

Yes, we used the "multivariable".

Line 162 -- Missing data were handled by list-wise deletion but how much missing data were there and for which variables? Was missing data on covariates associated with the outcome or covariates examined? The final sample size of the multivariable analyses should be included as a footnote in corresponding tables.

In this revision, we used Multiple Imputation(MI) to handle miss data. The missing data (CD4) was not significantly associate with the outcome in univariable analysis (p=0.0969), but it met the criterion for entering multivariable analysis (p\<0.1). We provided the final sample size of the multivariable analyses as a footnote in table 3.

Results:

Lines 170-176 -- Although a statement is provided comparing characteristics of individuals who were included in and excluded from the analytic sample, these data should be reported, perhaps as supplementary tables.

Yes, we provided the comparison as supplementary S1 Table.

Table 2 is difficult to interpret and the total column repeats data that was presented in Table 1.

It should be noted whether column or row percentages are presented and only one type should be provided in a given table. Table 2 currently seems to use both.

Yes, we realize this. We should read the manuscript several more times before submission. We shouldn't make such a stupid mistake. Please accept my sincere apology for my negligence in writing the Table 1 and 2. We omitted the total column of Table 2, because it repeated data presented in table 1.

Lines 266-267 -- The line "lower drug prevalence" is too vague.

Yes, we describe the lower prevalence in details.

Lines 267-268 -- The line "men had twice the prevalence of women" should specify the outcome. Prevalence of what?

Yes, it should be "Prevalence of the overall prevalence of TDR".

Line 290 -- It is incorrect to state "this trend became significance when controlling for potential confounders", as the trend was already statistically significant in univariate analysis.

Sorry, this is my negligence. We described this as "There was a significant decline in the prevalence of TDR over between 2001 and 2016 when both the univariable and multivariable analyses were performed".

Line 331 (Table 3) -- Why does the footnote for Table 3 specify "multilevel" regression was used? This contrasts what was written in the methods section.

Please forgive me for my negligence. We corrected this. The "multilevel" should be "mutivariable".

Line 333 -- Related to the missing data issue discussed above, there were at least 501 individuals (24% of 2,130) who were dropped from the multivariable analysis due to missing data on CD4 count. More rigorous methods to handle missing data should be explored or an explanation for why they were not pursued should be explained.

Thank you very much. Of all the comments, this is the most difficult and the most challenging one. The CD4 count was not significantly associate with TDR in univariable analysis (p=0.0969), but it met the criterion for entering multivariable analysis (p\<0.1). To reply this comment, we did three things.

Firstly, we analyzed the missing of CD4 count by sampling periods and found that CD4 data missing mainly occurred in patients that were diagnosed during 2001-2008 and 2015-2016(Table 1).In early stage, the CD4 missing was easy to understand. At that time, the HIV epidemiology database was just established and in its commencement. There was possibility that some CD4 counts record were not input into the database. Moreover, we still did not begin to provide the free CD4 test. Many patients might not take the CD4 test. The CD4 miss during 2015-2016 should mainly attribute to "HIV/AIDS information leak Affaire in 2016".In July, 2016, HIV/AIDS individuals' private information in China was leaked, a lot of illegal events related to HIV/AIDS individuals occurred, for instance, the telecommunication fraud. Hence, the government of China has required the strict management of HIV/AIDS individuals' information according to Regulations on AIDS prevention and control and Law of Infectious disease prevention and control. The maintaining of national HIV epidemiological database was discontinuedfor nearly a year. During that time, the CD4 count data were not recorded in the database. Now, though the database has resume normal, the missing CD4 has not yet been added into the database. We are sure that most of the individuals diagnosed during 2015-2016 have CD4 counts records. These records are stored in the HIV laboratory.

Secondly, we do our best to trace these CD4 records and re-input it into the database. Our colleagues Juan Wang and Jing Chen took three weeks to finish the job-501 records, one by one. After these efforts, we get back 229 CD4 record. The total CD4 missing rate fall to 12.7%(Table 2). Ironically, after adding these missing CD4 counts, the CD4 count was still not significantly associate with TDR in univariable analysis (p=0.8), moreover it also did not meet the criterion for entering multivariable analysis (p\<0.1).

Thirdly, more powerful methods were used to handle the missing data. The statistical method in this article stemmed for the "R in Action: Data Analysis and Graphics with R" by Robert I. Kabacoff. This book provided four method of handling miss data: list-wise deletion, case-wise deletion, simple imputation, and multiple imputation. Most popular statistic software used list-wise deletion to handle miss data by default. That was what had happened in the previous draft. As recommended in the textbook, we used multiple imputation(MI) in this revision and tried the other three methods. The results of the analysis using the four methods were consistent. Therefore, the missing of 12.7% CD4 count did not affect the final conclusion of this study.

Table 1. The CD4 missing by sampling period in the first draft

Period CD4 missing(n) Total(n) Rate of CD4 missing(%)

2001-2008 152 357 42.6

2009-2011 105 497 21.1

2012-2014 42 731 5.7

2015-2016 202 545 37.1

Total 501 2130 23.5

Table 2. The CD4 missing by sampling period in the new draft

Period CD4 missing(n) Total(n) Rate of CD4 missing(%)

2001-2008 143 357 40.1

2009-2011 97 497 19.5

2012-2014 16 731 2.2

2015-2016 16 545 2.9

Total 272 2130 12.7

Discussion

Line 337 -- It is unclear how this is a "prospective" study if sequences prior to routine genotyping were examined for TDR retrospectively.

Our study is mainly a prospective study. In 2001-2005, it is retrospective, and in 2006-2016, it is prospective. Since 2,056 of 2,130 of the plasma were collected during 2006-2016, we believed that our study is 96.5%prospective.

Lines 389-392 -- The discussion states that the data presented in this study "\[assist\] in the development of prevention and treatment strategies to influence the HIV epidemic within Beijing." Further elaboration on how would be helpful.

We think our findings would be helpful in the following aspects:

1\. Because most patients are sensitive to first-line regimens, the routine genotype testing is not required, and there is no pressing need for expensive second-line regimens.

2\. Although NFV is not used as part of first-line ART regimens in Beijing, we noted at least low-level TDR to these drugs in 1.9% of individuals. Thus, the use of NFV in Beijing should be examined with caution.

3\. Vaccine designer in Beijing should take the fact that CRF01_AE, CRF07_BC and subtype B constituted more than 90% of all the clades into consideration in select appropriate candidate HIV strains. Viral load (VL) kit manufacturer should also know this in designing the primer to ensure accurate HIV RNA quantitation of non-B subtypes in Beijing.

Nonresponse should be discussed in further detail.

Yes, every HIV molecular epidemiology study will be inevitably subject to the caveat of non-response or the non-genotype. To our knowledge, there was no HIV molecular epidemiology with large sample size could genotype 100% of the samples. We believe that our 92% genotype rate is acceptable. In fact, non-genotype mainly took place for the plasma sample collected during period 2001-2008. It was supposed that the viral load tend to decline the longer they are preserved. We could not expect that the genotype rate in sample collected two decade before, preserved in refrigerator for 20 years, be as high as that for fresh blood collect today. In early days, preservation of sample was not seriously regarded. Samples were preserved wherever they could find, some times in -80℃ refrigerators, some times in -40℃, even in -20℃. Our laboratory then boasted only one -80℃ refrigerator. I could do nothing with this, because I was only a college student and I did not work here. We should thank our pioneer colleagues; it was they preserve the golden-like sample. As time passed, things changed a lot. We accumulate a lot of experience of genotyping during past decade. In the early stage, when in-house TDR genotype test was first introduced in Beijing. We copy the experiment without modification. We used subtype B primer, and we only concerned the genotype, without giving consideration to the non-genotype. What we got is what we analyzed. Then we could genotype 60%-80% of the samples. We did not take effort to repeat the test in the non-genotype. Things changed. Practice make perfect. During the past decade, I read carefully about 200 classical HIV epidemiology paper and I took more than ten HIV epidemiology course. In the end, we realize that the representation the non-genotype is of the same importance as the genotype. We also accumulated lots of practical experience of TDR test. We designed our own subtype specific primer. To improve the genotype rate, we usually carry out genotype test for three rounds. In first round, we use CRF01_AE specific primer. In second round, we use the CRF07_BC and subtype B specific primer both. In the third round, we use concentrated RNA template without adding water with all the three above mentioned primers. After three rounds of tests, we usually genotype about 90% of the samples. In this study, we compared the demographic characteristics of individuals with genotype vs. those with non-genotype. We show that the characteristics were broadly similar between individuals with and without genotyped virus. Therefore, we believed that the 8% non-response would not affect the final conclusion.

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

Yes, we visited the PACE web more than ten times; however, this URL was never available in Beijing, if only once. However, we fully understood the PLOS requirements for figures. That is TIFF or EPS in file; width: 789 -- 2250 pixels (at 300 dpi), height maximum: 2625 pixels (at 300 dpi), in dimensions; 300 -- 600 dpi for resolution; file Size\<10 MB, Arial, Times, or Symbol font only in 8-12 point text within Figures. We are sure that our two figures met the requirement.

###### 

Submitted filename: plos one comment5.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0230779.r003

Decision Letter 1

Blackard

Jason

Academic Editor

© 2020 Jason Blackard

2020

Jason Blackard

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2 Jan 2020

PONE-D-19-15622R1

Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001-2016

PLOS ONE

Dear Dr. Lu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please revise the manuscript based on the minor comments from Reviewer \#2.  Also ensure that they manuscript has been reviewed thoroughly by a native English speaker and/or professional editing service.

We would appreciate receiving your revised manuscript by Feb 16 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Jason Blackard, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Please revise the manuscript based on the minor comments from Reviewer \#2.  Also ensure that they manuscript has been reviewed thoroughly by a native English speaker and/or professional editing service.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have addressed all the observations raised. The manuscript could be accepted for the publication.

Reviewer \#2: The revised manuscript is substantially improved; however, one issue remains pertaining missing data.

The revised methods section states multiple imputation was used to handle missing data. However, the footnotes of the tables indicate differential sample sizes for certain variables. For instance, there were a total of 2130 sequences, but the number of sequences for each stratum of CD4 count interval in Table 3 only sums to 1858 (473+519+455+411). Further, the discussion states, \"When missing, the CD4 counts was imputed, but imputation was only required for 454 12.8% of the study population.\" Did the authors only account for imputation in the regression analyses but not the descriptive data? If so, this is not standard practice and should be explained.
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Dear Editor and Reviewers:

We would like to thank Plos One for giving use the opportunity to revise our manuscript. We thank the reviewer for this pertinent and insightful comment. We have carefully taken their comments into consideration in preparing our revision. Below is our response to their comments.

Reviewer \#2: The revised manuscript is substantially improved; however, one issue remains pertaining missing data.

The revised methods section states multiple imputation was used to handle missing data. However, the footnotes of the tables indicate differential sample sizes for certain variables. For instance, there were a total of 2130 sequences, but the number of sequences for each stratum of CD4 count interval in Table 3 only sums to 1858 (473+519+455+411). Further, the discussion states, \"When missing, the CD4 counts was imputed, but imputation was only required for 454 12.8% of the study population.\" Did the authors only account for imputation in the regression analyses but not the descriptive data? If so, this is not standard practice and should be explained.

Reply:

As discussed in this our previous response (see above), we used listwise deletion method to handle the missing data. We also attempted to use the more powerful method-multiple imputation. The introduction of multiple imputations added more problems in the analysis. As kindly mentioned by the reviewer, the imputation in the regression analysis is not a more conventional and widely used standard practice. This is now dropped in our final analysis.

The data missing in our cohort mainly occurred for age (0.2%), transmission risk group (2.2%) and CD4 counts (12.8%). We think the effect of data missing in the first two variables on the association were negligible, therefore we mainly focus on the data missing in CD4 counts. Referring on the literature on how to handle the problem of miss data, at least ten HIV TDR articles published in Lancet infectious disease, Lancet HIV, CID, JID, AIDS, and Plos One within the past ten years were used to guide our analysis. Of the ten papers, only one in JID used listwise method to handle miss data\[1\]. The remaining nine articles did not mention what method was used to handle miss data\[2-10\]. Since the most popular statistic software used listwise deletion to handle miss data by default, we have assumed that the listwise method was used. On the contrary, multiple imputation was never mentioned at all.

Therefore, we decide to use listwise method rather the multiple imputation to handle the missing data throughout the article. Nevertheless, we did also try multiple imputation to handle CD4 missing in logistics analysis(S2 Table). The results from listwise and multiple imputation were consistent.

Moreover, when four sensitivity experiments were carried out by excluding individual sampling phase(S3-6 Table, the association between CD4 and TDR was still not significant.

If the missing data were assumed to be missing at random and multiple imputation was truly employed to handle missing data, the methods section should provide more details on how and why multiple imputation was conducted. What variables had missing data and what percentage? What variables had missing data imputed? What variables were considered in the imputation model? How many imputed data sets were used?

Reply:

Age (0.2%), transmission risk group (2.2%) and CD4 counts (12.8%) had missing data. CD4 counts had missing data imputed. CD4 variable was considered in the imputation model. Five imputed data sets were used.

The program for multiple imputation in R was list below:

library(lattice)

library(MASS)

library(nnet)

library(mice)

imp\<-mice(data,m)

fit\<-with(imp,analysis)

pooled\<-pool(fit)

summary(pooled)
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Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The authors have satisfied previous concerns. The revised manuscript now clearly states list-wise deletion was used to handle missing data in primary analyses. In addition, the manuscript now includes a sensitivity analysis using multiple imputation for the association of CD4 count and drug resistance (Supplemental Table 2).

Two minor comments:

Methods (page 9, Line 175): Please revise the sentence, \"However when CD4 data were missing the multiple imputation was applied to perform logistics analysis.\" to read: \"However, since 12.8% of data were missing for CD4 count, a sensitivity analysis was performed using multiple imputation to handle missing data (m=5).\"

Please check p values in Table 3. The adjusted odds ratio for women was 0.26 (0.04-0.85) but the p value is \>0.05 (i.e., p=0.06). The p value for this effect size and CL limit \<1 would be expected to have a p value \<0.05.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 2

6 Mar 2020

Dear Editor and Reviewers:

We would like to thank Plos One for giving use the opportunity to revise our manuscript. We thank the reviewer for this pertinent and insightful comment. We have carefully taken their comments into consideration in preparing our revision. Below is our response to their comments.

Two minor comments:

1\. Methods (page 9, Line 175): Please revise the sentence, \"However when CD4 data were missing the multiple imputation was applied to perform logistics analysis.\" to read: \"However, since 12.8% of data were missing for CD4 count, a sensitivity analysis was performed using multiple imputation to handle missing data (m=5).\"

Yes, we did it. This sentence is far more accurate than the former one.

2\. Please check p values in Table 3. The adjusted odds ratio for women was 0.26 (0.04-0.85) but the p value is \>0.05 (i.e., p=0.06). The p value for this effect size and CL limit \<1 would be expected to have a p value \<0.05.

Thank you for your serious and careful proofreading. As the first author, though I have read the manuscript for more than 20 times, I still did not notice this inconsistence in Table 3. Honestly, when I first got this comment, my hair stood on end. Because this inconsistence could mean that either the OR or the p value is wrong. If it is true, the overall result of logistic analysis could be overthrew. That will be a nightmare for me. Fortunately, when I double checked the result of logistic analysis, I confirmed that there is no wrong in our logistic analysis. Therefore, the final question could be summed up as \"Should the CI of OR always be consistent with the p value?\" This question sounds like unprofessional. But it is the truth under our circumstance. Why is that so? We speculated that the sample size of women is too small to reach significance. The number of women in our study is trivial compared with the number of men( 151 vs 1979). Our recent national survey with larger sample size of women confirms that our speculation is correct. Moreover, the Chi-squared test also showed that the difference is non-significant(x-squared=3.0, p value=0.08).

Finally, we will like to express my appreciation for all these insightful comments and hard work in this reviewing. I learnt a lot of statistical knowledge in the submission. Yes, the process of submission is also the process of learning.

We hope that our revision is acceptable, and we look forward to hearing from you soon.

###### 

Submitted filename: plos response.docx

###### 

Click here for additional data file.
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10 Mar 2020

Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001-2016

PONE-D-19-15622R3

Dear Dr. Lu,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jason Blackard, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

None

Reviewers\' comments:

None
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13 Mar 2020

PONE-D-19-15622R3

Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001-2016

Dear Dr. Lu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jason Blackard

Academic Editor

PLOS ONE
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